Cocrystal Pharma, Inc. (COCP) - Earnings growth in current year

Cocrystal Pharma, Inc. (COCP) ensures resilience through the development of treatments against coronavirus, influenza, and norovirus. The brand's scientific authority is based on the application of protein crystallography in the creation of new antiviral agents. The company is currently actively developing a line of universal drugs within clinical trials. Year-over-year EPS dynamics reflect market expectations, where 7.10 captures the current value of the indicator.

COCP Cocrystal Earnings growth in current year (07/04/2022 - 11/15/2026)

Financial and market metric breakdowns for Cocrystal Pharma Inc (COCP)

- stock price and consensus target price:

Price Performance Chart Cocrystal Pharma, Inc.|COCP - Consensus Target

- market capitalization indicators:

Market Capitalization Cocrystal Pharma, Inc.|COCP - Total Company Value

- book capitalization data:

Net Assets per Share Cocrystal Pharma|COCP - Book Capitalization|Market Cap to Net Assets Ratio cocrystalpharma.com|COCP - Aggregate Company Assets

- debt and liquidity details:

- earnings and multiples data:

COCP - Net Income|Future Net Profit Cocrystal Pharma, Inc.|COCP - P/E Multiple|Forward P/E Multiple cocrystalpharma.com|COCP - Price/Earnings to Growth Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Cocrystal Pharma Inc|COCP - Operating profit before deduction of amortization|Earnings per share for the trailing year Cocrystal Pharma|COCP - Earnings per share for the last twelve months|Year-over-year net earnings per share trend for the last twelve months cocrystalpharma.com|COCP - Earnings growth in current year|Expected earnings per share trend next year Cocrystal Pharma, Inc.

- sales volume and revenue information:

COCP - Revenue and Sales Volume|Projected Sales Volume Cocrystal Pharma Corp|COCP - Price-to-Revenue Ratio|Forward Price to Sales Cocrystal Pharma, Inc.

Basic company analysis:Cocrystal Pharma, Inc. (COCP)

Conservative capital demands absolute transparency in yield dynamics to assess business sustainability. This indicator measures the annual percentage change in net income per share, reflecting the efficiency of capital generation. For Cocrystal Pharma, Inc. (COCP), with its focus on small molecule clinical trials, such a metric reveals the impact of R&D expenditures on the bottom line. Analyzing the current EPS YoY growth rate allows investors to filter out market noise, confirming the issuer's actual financial health.

Key competitors